多医院医疗系统中极低危前列腺癌的当代诊断
研究基于11家医院系统2018至2023年数据,351/3197(11%)例前列腺癌患者符合NCCN极低危标准。尽管MRI引导穿刺比例从49%升至82%(p<0.001),极低危诊断比例未见变化(p=0.8)。联合系统与靶向穿刺时,79%的极低危癌发现于系统穿刺区域,31%见于靶向穿刺区域。
要点
- 2018至2023年极低危前列腺癌占诊断的11%(351/3197),比例未随时间变化(p=0.8)。
- MRI引导穿刺比例从49%升至82%(p<0.001),但极低危诊断比例未下降。
- 联合穿刺时79%极低危癌见于系统穿刺区域,31%见于靶向穿刺区域。
核心结论
- 极低危前列腺癌仍占诊断的显著 minority,靶向穿刺和风险分层计算器可能限制其诊断。
研究设计与样本
- 基于11家医院系统2018至2023年数据的回顾性分析,纳入3197例前列腺癌患者。
主要发现
- 351/3197(11%)例符合NCCN极低危标准,2018至2023年比例无变化(p=0.8)。
- MRI引导穿刺比例从49%升至82%(p<0.001)。
- 联合系统与靶向穿刺确诊的极低危病例中,79%见于系统穿刺区域,31%见于靶向穿刺区域。
- 联合穿刺时,基于穿刺前MRI的风险计算器以Gleason分级分组≥3前列腺癌风险>5%为活检阈值,可减少41%的极低危诊断;仅行靶向穿刺时减少77%。
临床怎么用
- 作者认为,使用风险计算器识别可避免活检的男性,和/或仅对MRI可见病灶进行活检,可能减少极低危前列腺癌的过度诊断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The National Comprehensive Cancer Network (NCCN) very low risk (VLR) category for prostate cancer (PCa) represents clinically insignificant disease, and detection of VLR PCa contributes to overdiagnosis. Greater use of magnetic resonance imaging (MRI) and biomarkers before patient selection for prostate biopsy (PBx) reduces unnecessary biopsies and may reduce the diagnosis of clinically insignificant PCa. We tested a hypothesis that the proportion of VLR diagnoses has decreased with greater use of MRI-informed PBx using data from our 11-hospital system. From 2018 to 2023, 351/3197 (11%) men diagnosed with PCa met the NCCN VLR criteria. The proportion of VLR diagnoses did not change from 2018 to 2023 (p = 0.8) despite an increase in the use of MRI-informed PBx (from 49% to 82%; p < 0.001). Of patients who underwent combined systematic and targeted PBx and were diagnosed with VLR disease, cancer was found in systematic PBx regions in 79% of cases and in targeted PBx regions in 31% of cases. When performing both systematic and targeted PBx, prebiopsy MRI-based risk calculators could limit VLR diagnosis by 41% using a risk threshold of >5% for Gleason grade group ≥3 PCa to recommend biopsy; the reduction would be 77% if performing targeted PBx only. These findings suggest that VLR disease continues to account for a significant minority of PCa diagnoses and could be limited by targeted PBx and risk stratification calculators. PATIENT SUMMARY: We looked at recent trends for the diagnosis of very low-risk (VLR) prostate cancer. We found that VLR cancer still seems to be frequently diagnosed despite the use of MRI (magnetic resonance imaging) scans before biopsy. The use of risk calculators to identify men who could avoid biopsy and/or biopsy only for lesions that are visible on MRI could reduce the overdiagnosis of VLR prostate cancer.
引用
- Bennett R, Li EV, Ho AY, et al. Contemporary Diagnosis of Very Low-risk Prostate Cancer in a Multihospital Health Care System. Eur Urol Oncol. 2024. PMID: 38734544. doi:10.1016/j.euo.2024.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。